Valeant Pharmaceuticals International Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops and markets specialty pharmaceutical, branded generic and OTC products that make a meaningful difference in patients' lives. We are focused primarily on the neurology and dermatology therapeutic areas in the United States, Canada, and Australia markets, while operating branded generics businesses in Latin America and Europe. Based in Orange County, California, we employ approximately 2,300 people worldwide. Throughout 2008, Valeant's new management team simplified and refocused our business strategy to concentrate on the company's strengths in the neurology and dermatology therapeutic areas. We plan to maximize our pipeline through strategic partnering to optimize our research and development assets and strengthen ongoing internal development capabilities. During the year, we made significant strides and divested our licensing rights in Argentina, the Asia Pacific region, Western and Eastern Europe, and the Middle East. Additionally, we signed an exclusive worldwide partnership agreement with GSK for retigabine, our Phase III compound. Valeant also entered into a join venture agreement with Meda AB to strengthen its presence in Canada, Mexico and Australia At Valeant, we never lose sight of why we are in business - to improve the health and enhance the lives of our patients through innovative medicines and products Valeant Canada Limited Valeant Canada is a specialty pharmaceutical company and is a subsidiary of Valeant Pharmaceuticals International. Valeant Canada manufactures and markets pharmaceutical products, primarily in the areas of Neurology, Psychiatry, Pain Management, and Dermatology. Based in Montreal, Quebec, Valeant Canada employs 160 people. IMS Health (Canada) ranked Valeant Canada as part of the ten (10th) fastest growing pharma companies in the last three years (2008).